세계의 분자세포 유전학 시장 보고서 : 제품 유형, 기술, 용도, 최종 사용자 및 지역별(2024-2032년)

The global molecular cytogenetics market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032.

Molecular cytogenetics refers to the biomedical research of deoxyribonucleic acid (DNA) mechanisms to investigate genetic mutations and disorders. It studies the structural and functional organization of the chromosomes and their nucleus, genomic variations, expression, evolution and abnormalities, especially in medicinal and cancer-related genetics. Techniques such as DNA amplification, DNA isolation, gene screens, virtual karyotyping and fluorescence in situ hybridization (FISH) are commonly used for molecular cytogenetics by using DNA probes to visualize and label the genome or its targeted regions. These techniques are highly beneficial in the diagnosis and treatment of various malignant tumors and hematological malignancies.

The increasing prevalence of cancer and other genetic disorders, along with the rising geriatric population, is one of the key factors driving the growth of the market. Molecular cytogenetics is primarily being used for developing predictive models of disease traits and effective treatment strategies. Furthermore, the widespread adoption of targeted therapies for cancer treatment is also augmenting the market growth. FISH and Comparative Genomic Hybridization (CGH) are also used for pharmacogenomic biomarker studies to analyze cancer progression stages and provide personalized treatment to the patient. Additionally, various technological advancements, such as the development of improved consumables, reagents, software and kits, are acting as other growth-inducing factors. These advancements aid in generating duplicatable, accurate and reliable clinical-pathological test results. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biomedical sciences, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global molecular cytogenetics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, technology, application and end user.

Breakup by Product Type:

Instruments

Consumables

Software and Services

Others

Breakup by Technology:

Comparative Genomic Hybridization

Fluorescence in SITU Hybridization (FISH)

Immunohistochemistry

Karyotyping

Others

Breakup by Application:

Genetic Disorders

Oncology

Personalized Medicine

Others

Breakup by End User:

Clinical and Research Laboratories

Hospitals and Pathology Laboratories

Pharmaceutical and Biotechnology Companies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging Inc., Biological Industries, Bio-RAD Laboratories Inc., BioView Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., Oxford Gene Technology, Perkinelmer Inc. and Quest Diagnostics Incorporated.

Key Questions Answered in This Report

• 1. What was the size of the global molecular cytogenetics market in 2023?
• 2. What is the expected growth rate of the global molecular cytogenetics market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global molecular cytogenetics market?
• 4. What are the key factors driving the global molecular cytogenetics market?
• 5. What is the breakup of the global molecular cytogenetics market based on the product type?
• 6. What is the breakup of the global molecular cytogenetics market based on the technology?
• 7. What is the breakup of the global molecular cytogenetics market based on application?
• 8. What is the breakup of the global molecular cytogenetics market based on the end user?
• 9. What are the key regions in the global molecular cytogenetics market?
• 10. Who are the key players/companies in the global molecular cytogenetics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Molecular Cytogenetics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Instruments
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Software and Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Comparative Genomic Hybridization
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Fluorescence in SITU Hybridization (FISH)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunohistochemistry
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Karyotyping
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Application

• 8.1 Genetic Disorders
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Oncology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Personalized Medicine
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by End User

• 9.1 Clinical and Research Laboratories
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Hospitals and Pathology Laboratories
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Pharmaceutical and Biotechnology Companies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Agilent Technologies Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Applied Spectral Imaging Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Biological Industries
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Bio-RAD Laboratories Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 BioView Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Danaher Corporation
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 F. Hoffmann-La Roche AG
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 SWOT Analysis
  • 15.3.9 Illumina Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Oxford Gene Technology
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
  • 15.3.11 Perkinelmer Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Quest Diagnostics Incorporated
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials